377 related articles for article (PubMed ID: 33587814)
1. Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?
Celsa C; Cabibbo G; Enea M; Battaglia S; Rizzo GEM; Busacca A; Giuffrida P; Stornello C; Brancatelli G; Cannella R; Gruttadauria S; Cammà C
Liver Int; 2021 May; 41(5):1105-1116. PubMed ID: 33587814
[TBL] [Abstract][Full Text] [Related]
2. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
Zhang L; Hu P; Chen X; Bie P
PLoS One; 2014; 9(6):e100305. PubMed ID: 24945380
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
Choi GH; Shim JH; Kim MJ; Ryu MH; Ryoo BY; Kang YK; Shin YM; Kim KM; Lim YS; Lee HC
Radiology; 2013 Nov; 269(2):603-11. PubMed ID: 23864102
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study.
Wan YM; Li YH; Xu ZY; Wu HM; Xu Y; Yang M; Wu XN
Integr Cancer Ther; 2018 Jun; 17(2):477-485. PubMed ID: 29108428
[TBL] [Abstract][Full Text] [Related]
6. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Yang M; Yuan JQ; Bai M; Han GH
Mol Biol Rep; 2014 Oct; 41(10):6575-82. PubMed ID: 25091939
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Chen J; Zhou C; Long Y; Yin X
Tumour Biol; 2015 Jan; 36(1):183-91. PubMed ID: 25217986
[TBL] [Abstract][Full Text] [Related]
8. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
9. Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization.
Wang H; Li B; Wang Y; Zhang J; Wu Y; Fan W; Li J
J Cancer Res Ther; 2020; 16(2):301-308. PubMed ID: 32474517
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.
Zheng L; Li HL; Guo CY; Luo SX
Korean J Radiol; 2018; 19(2):237-246. PubMed ID: 29520181
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
[TBL] [Abstract][Full Text] [Related]
12. Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.
English K; Brodin NP; Shankar V; Zhu S; Ohri N; Golowa YS; Cynamon J; Bellemare S; Kaubisch A; Kinkhabwala M; Kalnicki S; Garg MK; Guha C; Kabarriti R
JAMA Netw Open; 2020 Nov; 3(11):e2023942. PubMed ID: 33151315
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Chemoembolization Followed by Radiotherapy Versus Sandwich Treatment for Unresectable or Ablative Hepatocellular Carcinoma.
Lin H; Wu H; Cong N; Liu B; Liu C; Han D
Technol Cancer Res Treat; 2020; 19():1533033820983799. PubMed ID: 33357168
[TBL] [Abstract][Full Text] [Related]
14. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
15. Corona Enhancement and Mosaic Architecture for Prognosis and Selection Between of Liver Resection Versus Transcatheter Arterial Chemoembolization in Single Hepatocellular Carcinomas >5 cm Without Extrahepatic Metastases: An Imaging-Based Retrospective Study.
Li M; Xin Y; Fu S; Liu Z; Li Y; Hu B; Chen S; Liang C; Lu L
Medicine (Baltimore); 2016 Jan; 95(2):e2458. PubMed ID: 26765441
[TBL] [Abstract][Full Text] [Related]
16. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Kudo M; Ueshima K; Ikeda M; Torimura T; Tanabe N; Aikata H; Izumi N; Yamasaki T; Nojiri S; Hino K; Tsumura H; Kuzuya T; Isoda N; Yasui K; Aino H; Ido A; Kawabe N; Nakao K; Wada Y; Yokosuka O; Yoshimura K; Okusaka T; Furuse J; Kokudo N; Okita K; Johnson PJ; Arai Y;
Gut; 2020 Aug; 69(8):1492-1501. PubMed ID: 31801872
[TBL] [Abstract][Full Text] [Related]
17. Thermal ablation alone vs thermal ablation combined with transarterial chemoembolization for patients with small (<3 cm) hepatocellular carcinoma.
Chai NX; Chapiro J; Petukhova A; Gross M; Kucukkaya A; Raju R; Zeevi T; Elbanan M; Lin M; Perez-Lozada JC; Schlachter T; Strazzabosco M; Pollak JS; Madoff DC
Clin Imaging; 2021 Aug; 76():123-129. PubMed ID: 33592550
[TBL] [Abstract][Full Text] [Related]
18. Thermal ablation combined with transarterial chemoembolization for hepatocellular carcinoma: What is the right treatment sequence?
Hendriks P; Sudiono DR; Schaapman JJ; Coenraad MJ; Tushuizen ME; Takkenberg RB; Oosterveer TTM; de Geus-Oei LF; van Delden OM; Burgmans MC
Eur J Radiol; 2021 Nov; 144():110006. PubMed ID: 34717187
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review.
Mulyadi R; Hasan I; Sidipratomo P; Putri PP
J Egypt Natl Canc Inst; 2024 May; 36(1):18. PubMed ID: 38797810
[TBL] [Abstract][Full Text] [Related]
20. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma.
Labeur TA; Takkenberg RB; Klümpen HJ; van Delden OM
Cardiovasc Intervent Radiol; 2019 Feb; 42(2):230-238. PubMed ID: 30488302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
